Vaccine Conjugates Companies

ID: MRFR/Pharma/0601-HCR

110 Pages

Nidhi Mandole

Last Updated: February 16, 2025

Vaccine conjugates companies specialize in the development and production of conjugate vaccines. Conjugate vaccines are created by combining a bacterial or viral antigen with a carrier protein, enhancing the immune system's response, particularly in the case of certain bacteria that have polysaccharide capsules. These vaccines are crucial in preventing infections caused by bacteria like Haemophilus influenzae type b (Hib), Streptococcus pneumoniae, and Neisseria meningitidis.

Vaccine Conjugates Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)8.34%

2024 Market Size$ 5.72 Billion

2025 Market Size$ 6.27 Billion

2035 Market Size$ 13.87 Billion

Key Players

Pfizer

Merck

GlaxoSmithKline

Sanofi

Novartis

AstraZeneca

Trends

Rising Demand for Combination Vaccines
Focus on Pediatric Vaccination
Advancements in Vaccine Technology

Opportunities

Market Growth Projections
Government Initiatives and Funding
Growing Awareness of Vaccine Benefits

Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Vaccine Conjugates Market

Latest Vaccine Conjugates Companies Updates

Pfizer Inc. (US): Received FDA approval for its Prevnar 20® pneumococcal conjugate vaccine for adults in October 2023, expanding its market reach and potential revenue stream.

Merck & Co., Inc. (US): Partnered with PATH (US) in September 2023 to develop and introduce a new MenB vaccine conjugate for low- and middle-income countries, addressing global health disparities.

GlaxoSmithKline plc (UK): Highlighted its ongoing development of a malaria vaccine conjugate in its recent investor presentation, showcasing its commitment to innovative vaccine solutions.

Bharat Biotech International Limited (India): Announced successful Phase 3 clinical trials for its Typhoid Conjugate Vaccine in July 2023, paving the way for potential market entry and wider access to this important vaccine.

Novavax, Inc. (US): Presented promising preclinical data for its respiratory syncytial virus (RSV) F protein conjugate vaccine candidate in September 2023, adding to the pipeline of potential new conjugate vaccines.

List of Vaccine Conjugates Key companies in the market:

Bharat Biotech (India)
GlaxoSmithKline Plc (UK)
Serum Institute of India
Sanofi Pasteur (France)
Merck and Company (US)
CSL Limited (Australia)
Pfizer Inc. (US)
Novartis AG (Switzerland)
Neuron Biotech (the US)
Biological E (India)

Customize Report

Certified Researchers

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”